

Are your MRI contrast agents cost-effective?

Learn more about generic Gadolinium-Based Contrast Agents.



AJNR

**Intracranial Dural Arteriovenous Fistulas:
Classification, Imaging Findings, and
Treatment**

D. Gandhi, J. Chen, M. Pearl, J. Huang, J.J. Gemmete and S.
Kathuria

This information is current as
of April 19, 2024.

AJNR Am J Neuroradiol published online 12 January 2012
<http://www.ajnr.org/content/early/2012/01/19/ajnr.A2798>

REVIEW ARTICLE

D. Gandhi
J. Chen
M. Pearl
J. Huang
J.J. Gemmete
S. Kathuria



Intracranial Dural Arteriovenous Fistulas: Classification, Imaging Findings, and Treatment

SUMMARY: Intracranial DAVFs are pathologic dural-based shunts and account for 10%–15% of all intracranial arteriovenous malformations. These malformations derive their arterial supply primarily from meningeal vessels, and the venous drainage is either via dural venous sinuses or through the cortical veins. DAVFs have a reported association with dural sinus thrombosis, venous hypertension, previous craniotomy, and trauma, though many lesions are idiopathic. The diagnosis is dependent on a high level of clinical suspicion and high-resolution imaging. Cross-sectional imaging techniques by using CT and MR imaging aid in the diagnosis, but conventional angiography remains the most accurate method for complete characterization and classification of DAVFs. The pattern of venous drainage observed on dynamic vascular imaging determines the type of DAVF and correlates with the severity of symptoms and the risk of hemorrhage.

ABBREVIATIONS CVD = cortical venous drainage; DAVF = dural arteriovenous fistula; DMSO = dimethyl-sulfoxide; FPCT = flat panel detector CT; *n*-BCA = *n*-butyl 2-cyanoacrylate; NHND = non-hemorrhagic neurologic deficit; SRS = stereotactic radiosurgery; TAE = transarterial embolization; TVE = transvenous embolization

Intracranial DAVFs are pathologic shunts between dural arteries and dural venous sinuses, meningeal veins, or cortical veins. DAVFs account for 10%–15% of intracranial arteriovenous malformations.¹ DAVFs are distinguished from parenchymal or pial arteriovenous malformations by the presence of a dural arterial supply and the absence of a parenchymal nidus.¹ Most DAVFs present in adulthood and are located in the transverse, sigmoid, and cavernous sinuses.² Pediatric lesions tend to be complex, often supplied by bilateral arterial feeders, and most frequently involve the torcular herophili, superior sagittal sinus, or large venous lakes.³

Etiopathogenesis

DAVFs are predominantly idiopathic, though a small percentage of patients have a history of previous craniotomy, trauma, or dural sinus thrombosis (Fig 1).^{4–7} Two etiologic hypotheses based around sinus thrombosis have been put forward. The first is that physiologic arteriovenous shunts between meningeal arteries and dural venous sinuses enlarge in response to elevated local venous pressure, resulting in a pathologic shunt.^{4,5,8} The second is that venous hypertension due to outflow obstruction causes decreased cerebral perfusion and promotes neoangiogenesis.^{4,9} Heritable risk factors for venous thrombosis, such as antithrombin, protein C, and protein S deficiencies, have furthermore been associated with DAVF occurrence.^{10,11} These findings implicate the role of an underlying hypercoagulability in the development of DAVFs. The etiology of pediatric DAVFs is thought to be congenital or a

result of birth trauma, infection, in utero venous thrombosis, or maternal hormones.³

Classification and Natural History

The DAVF venous drainage pattern determines the severity of symptoms and provides the foundation for the classification schemes (Tables 1 and 2) of Borden et al¹² and Cognard et al.¹³ Both of these systems associate CVD with increased risk of intracranial hemorrhage and nonhemorrhagic neurologic deficits.^{14–20}

The Borden classification system¹² stratifies lesions on the basis of the site of venous drainage and the presence or absence of CVD (Fig 2). Borden type I lesions have the direct communication of meningeal arteries with a meningeal vein or dural venous sinus and exhibit normal antegrade flow. Type II lesions have shunts between the meningeal arteries and dural sinus, with retrograde flow into the subarachnoid veins, causing venous hypertension. Type III lesions have direct drainage of meningeal arteries into subarachnoid veins or an “isolated” sinus segment. The latter phenomenon is the result of thrombosis on either side of the arterialized sinus segment, which directs retrograde flow into the subarachnoid venous system. The Borden classification scheme further subclassifies lesions as single-hole (a) or multiple-hole (b) fistulas.

The Cognard classification¹³ is based on the direction of dural sinus drainage, the presence or absence of CVD, and venous outflow architecture (nonectatic cortical veins, ectasia cortical veins, or spinal perimedullary veins). Type I lesions drain into the dural sinus, have an antegrade flow direction, and lack CVD. Type II lesions are subdivided in 3 subcategories: type IIa lesions drain retrogradely into a dural sinus without CVD, type IIb lesions drain antegradely into a dural sinus with CVD, and type IIa + b lesions drain retrogradely into a dural sinus with CVD. Types III, IV, and V lesions all have CVD, absent dural venous drainage, and varying cortical venous outflow architecture (Tables 1 and 2).

Lack of CVD (Borden type I, Cognard types I, IIa) is a favorable feature and is associated with a benign natural history. These patients typically present incidentally or with

From the Division of Interventional Neuroradiology (D.G., J.C., M.P., S.K.), Department of Radiology, and Department of Neurosurgery (J.H., S.K.), Johns Hopkins University School of Medicine, Baltimore, Maryland; and Department of Radiology and Otolaryngology, Head and Neck Surgery (J.J.G.), University of Michigan, Ann Arbor, Michigan.

Please address correspondence to Dheeraj Gandhi, MBBS, MD, Division of Interventional Neuroradiology, Department of Radiology, University of Maryland, 22 South Greene St, Baltimore, MD 21201; e-mail: dgandhi@um.edu



Indicates open access to non-subscribers at www.ajnr.org

<http://dx.doi.org/10.3174/ajnr.A2798>




Fig 1. A 53-year-old man with a history of head trauma presented with seizures and right-arm weakness. MR imaging (not shown) demonstrated bilateral parietal hemorrhage and thrombosis of the sagittal sinus. A–C, Sequential sagittal maximum intensity projections from a 320-section dynamic CTA demonstrate a subtle DAVF of the superior sagittal sinus (SSS) supplied by the anterior division of the left middle meningeal artery (arrows). Note the early opacification of the SSS. Venous phase image (C) demonstrates multiple filling defects (asterisk) in the SSS, consistent with SSS thrombosis. D–F, Correlative DSA of the left external carotid artery confirms the DAVF.

Table 1: Borden classification of DAVFs ¹²		
Type	Venous Drainage Site	CVD
"Benign"		
I	Dural sinus	No
"Aggressive"		
II	Dural sinus	Yes
III	Cortical vein	Yes

symptoms of increased dural venous drainage (eg, pulsatile tinnitus, exophthalmos). The risk of intracranial hemorrhage from Borden type I (Cognard types I, IIa) lesions is extremely low.^{16,18}

In either classification scheme, the presence of CVD (Borden type II and III, Cognard types IIb–V) is an aggressive feature that places DAVFs in a higher risk category. In these lesions, an annual mortality rate of 10.4%, an annual risk of intracranial hemorrhage of 8.1%, and annual risk of NHND of 6.9% have been reported.¹⁴ Subdividing lesions with CVD (Borden types II and III, Cognard types IIb–V) into symptomatic and asymptomatic types may further improve the accuracy of risk stratification.¹⁸ Zipfel et al¹⁸ demonstrated a significant difference in the risk of annual hemorrhage between symptomatic and asymptomatic types: 7.4% versus 1.5%, respectively.

Although classifying DAVFs is helpful for risk stratification, one should be aware that these lesions have a dynamic nature. Type I lesions can develop CVD with time due to the development of venous stenosis, venous thrombosis, or increased arterial flow.^{19,20} The risk of conversion is low, having only been reported in 2% of low-grade lesions.¹⁹ Cases of spontaneous thrombosis/resolution of DAVFs have also been reported.^{21–27} Any change in a patient's symptoms can reflect exacerbations of the venous drainage pattern and prompt further imaging work-up.

Clinical Presentation

A majority of patients with DAVFs present in the fifth and sixth decades with symptoms related to lesion location and

Table 2: Cognard classification of DAVFs ¹³			
Type	Venous Drainage	Flow Pattern in Sinus	CVD
"Benign"			
I	Dural sinus	Antegrade	No
IIa	Dural sinus	Retrograde	No
"Aggressive"			
IIb	Dural sinus	Antegrade	Yes
IIa+b	Dural sinus	Retrograde	Yes
III	Cortical vein		Yes
IV	Cortical vein		Yes + venous ectasia
V	Cortical vein with spinal perimedullary drainage		Yes

pattern of venous drainage.²⁸ Pulsatile tinnitus is a common symptom that results from increased blood flow through the dural venous sinuses, particularly in relation to transverse and sigmoid sinus lesions.^{13,18,19} Cavernous sinus DAVFs can present with ophthalmoplegia, proptosis, chemosis, retro-orbital pain, or decreased visual acuity.^{4,12,14}

Severe presentations include intracranial hemorrhage and nonhemorrhagic neurologic deficits such as seizures, parkinsonism, cerebellar symptoms, apathy, failure to thrive, and cranial nerve abnormalities, including rare cases of trigeminal neuralgia.^{28–33} Some symptoms, including dementia and cognitive decline, may improve after treatment.³⁴ Hemorrhagic presentations are more frequent in high-grade (Borden types II and III, Cognard types IIb to IV) DAVFs. Unexplained subarachnoid or lobar hemorrhages should prompt consideration of a DAVF in the differential diagnosis.

Diagnosis

Initial radiologic evaluation includes CT and MR imaging. Noncontrast CT is limited to identifying intracranial hemorrhage and edema due to venous congestion. MR imaging is




Fig 2. Schematic overview of the Borden system of classification for DAVFs. *A*, Type 1 fistula with multiple communications between the occipital artery and transverse sinus. Note antegrade flow and no cortical venous reflux. *B*, Type 2 lesions are associated with cortical venous reflux. This illustration demonstrates the presence of a transverse sinus fistula with stenosis of the distal transverse and proximal sigmoid sinuses. There is retrograde blood flow into the proximal transverse sinus and the cortical vein (please also see Fig 1E, -F). *C*, Type 3 fistulas represent communication between the meningeal arteries and cortical vein (or an isolated segment of venous sinus). In this schematic drawing, the cortical vein harboring the fistula near the frontal convexity is tortuous and has multifocal stenoses in its pathway, 2011 Lydia Gregg.

more helpful because it can demonstrate dilated vessels, venous pouches, vascular enhancement, and signs of venous hypertension in high-grade lesions (eg, white matter hyperintensity, intracranial hemorrhage, or venous infarction). These findings, however, vary with the type of DAVF investigated. Type I and II lesions may reveal flow-void clustering, engorged ophthalmic veins, or proptosis, whereas aggressive type II or III lesions are more likely to show dilated vessels, prominent vascular enhancement,¹ and hemorrhage.

Any suspicious flow void cluster around the dural venous sinus should prompt additional evaluation with dynamic CTA, MRA, or DSA.¹ CTA is particularly useful in treatment planning by precisely defining the arteriovenous shunt relative to surrounding brain and skull anatomy. Recent publications on 4D CTA by using 320-section multidetector row CT angiography have highlighted its potential to correctly diagnose, classify, and assist treatment planning for DAVFs (Fig 1).^{35,36} Studies have reported, however, that CTA has reduced sensitivity versus MRA for the detection of DAVFs (15.4% versus 50%).³⁷ Time-resolved MRA techniques are also promising and may be reliable for DAVF screening and surveillance in the future.^{38,39} Due to current limitations of low resolution, restricted FOV, and saturation artifacts, the negative predictive value of MRA is inadequate to exclude DAVFs.⁴⁰

Conventional angiography remains the most accurate method for detection and classification of DAVFs.¹⁵ The adjunct of FDCT to angiography is yielding previously unachievable high-resolution anatomic detail. Groups have demonstrated the utility of FPCT to precisely delineate the fistula site and provide superior visualization of arterial feeders and venous outflow.^{41,42}

Treatment

Endovascular approaches have become the mainstay of DAVF therapy, but the optimal approach for each case should involve

discussions among a multidisciplinary team of interventional neuroradiologists, neurosurgeons, neurologists, and radiation oncologists. Careful assessment of a patient's clinical presentation, current status (age, medical condition, comorbidities), and type of lesion (location, classification, and angiographic features) should be conducted before embarking on any treatment.

The risk of treatment should always be weighed against the natural history and expected clinical course of the lesion. High-grade lesions should be treated early to avoid the risks of hemorrhage and NHND. Conservative treatment is generally indicated in patients with low-grade fistulas (Borden I; Cognard I, IIa). Close follow-up is necessary to assess the development of new symptoms or progression of existing ones. Low-grade lesions with severe debilitating symptoms (eg, severe tinnitus or visual symptoms resulting in poor quality of life) are, however, candidates for prompt endovascular repair.

Endovascular Therapy

During the past 2 decades, embolization by using transarterial, transvenous, or, occasionally, combined approaches has become a first-line treatment for DAVFs. Treatment is aimed at complete elimination of the arteriovenous shunt—incomplete treatment allows recruitment of collateral vessels and persistent risk of hemorrhage. When complete occlusion of the shunt is not feasible or considered too risky, selective disconnection of CVD should be considered. This approach can have an efficacy comparable with DAVF obliteration in preventing neurologic morbidity with lower levels of procedural risk.^{43,44}

The optimal method of endovascular treatment remains debated and controversial. A consideration of the advantages and disadvantages of transarterial, transvenous, and combined approaches should be given in each case before proceeding with embolization.




Fig 3. A 52-year-old man presented with severe headache, slurred speech, and acute left hemiparesis. *A*, Noncontrast CT reveals a large right frontoparietal hematoma with intraventricular extension. *B–D*, A DAVF was suspected on MR imaging (not shown), and DSA was performed. Right (*B*), left (*C*), and bilateral (*D*) external carotid artery injections confirm a convexity DAVF (Borden type 3) with arterial supply from the bilateral middle meningeal and superficial temporal arteries. Transarterial treatment was planned by using the right middle meningeal artery approach (*D*). A microcatheter was navigated close to the fistula, and the embolization was performed with 2.3 mL of Onyx (*E*). Note the penetration of Onyx into the arteriovenous junction and the proximal vein (asterisk) as well as arterioarterial reflux (arrows) into the contralateral feeders. *F*, Ipsilateral (not shown) and contralateral external carotid artery injections confirm complete occlusion of the fistula. The patient made a remarkable recovery during the next 3 months and has mild residual left-arm weakness.

TAE

A vast majority of DAVFs lend themselves to treatment via a transarterial approach. In cases in which the fistula site involves a highly stenotic, compartmentalized, or isolated sinus⁴⁵ or a relatively small and tortuous cortical vein, TAE may be the only option because a transvenous option is difficult or impossible (Fig 3).⁴⁶

TAE involves superselective distal catheterization of arterial feeders. Ideally, the microcatheter tip should be “wedged” in the feeding artery and the embolic agent should penetrate the fistulous connection and proximal aspect of the venous receptacle.^{47–49} Available embolic agents include particles, coils, ethanol, *n*-BCA glue, and Onyx (ev3, Irvine, California).^{41,45,47,49} Particles should generally be avoided because complete durable fistula obliteration is usually impossible, allowing subsequent recanalization from collateral recruitment.^{42,47} Coils can be used as an adjunct to liquid embolic agents to reduce the rate of shunt surgery in high-flow lesions but are not usually curative when used alone.

n-BCA has been extensively used for TAE during the past 3 decades.⁴⁹ It is injected in liquid form and solidifies on contact with ionic solutions such as blood, resulting in occlusion of the desired vascular bed. The injection duration needs to be fairly short, and an experienced operator is essential. The thrombogenic properties of *n*-BCA can promote progressive

occlusion of residual shunt flow seen on immediate posttreatment angiography.⁴⁹ Several studies have demonstrated excellent cure rates by using *n*-BCA for TAE.^{47–49} However, multiple procedures are often necessary, and >1 treatment approach can be required (eg, transvenous, transarterial therapy, and/or operative resection) for complex lesions.^{48,50} Caution should be exercised to avoid accidental embolization of the distal venous system. This complication may result in progressive venous occlusion, exacerbation of venous hypertension, and/or venous infarction.^{48,50}

The use of Onyx has been increasingly reported for the treatment of DAVFs.^{41,45,48} This nonadhesive embolic agent consists of ethylene-vinyl alcohol copolymer dissolved in various concentrations of DMSO with micronized tantalum powder for radiopacity. On contact with blood, DMSO rapidly diffuses from the mixture, causing in situ precipitation of the polymer without adhesion to the vascular wall. The polymer initially precipitates within the peripheral area of the blood vessel, with secondary occlusion of the central vessel. This allows a longer more controlled injection with better penetration of the vascular bed compared with *n*-BCA.⁵¹ The operator also has the option of stopping the injection if Onyx begins to track toward another arterial pedicle, venous outflow vessel, or suspected dangerous anastomoses. The injection can then be restarted after several seconds because Onyx




Fig 4. A 43-year-old woman with Factor V Leiden mutation developed a spontaneous left-sided dural type (indirect) carotid cavernous fistula (CCF) with proptosis, chemosis, and left cranial nerve VI paralysis. *A* and *B*, Lateral view of the left internal carotid artery (ICA) injection and a left ICA 3D reconstruction demonstrates a moderate-flow CCF supplied from multiple left cavernous ICA branches. Additional supply also originated from left external carotid artery (ECA) and right ECA branches (not shown). Given the small size and multiplicity of feeders, transvenous treatment was favored. *C* and *D*, A microcatheter was navigated from the left facial vein into the left superior ophthalmic vein (arrows). The cavernous sinus was filled with coils (arrowhead), resulting in complete obliteration of the fistula (*D*). The proptosis and chemosis resolved the same day, and improvement of left cranial nerve VI function was already evident on postoperative day 1.

will track toward the low-pressure environment of the residual fistula. Another technical advantage of Onyx is the possibility of obtaining control angiograms during the embolization. This allows assessment of the remaining fistula flow and the changing hemodynamic pattern of a complex lesion. A major advantage of Onyx is the ability to cure complex multifeeder fistulas via a single pedicle (Fig 3).⁴⁹ Excellent cure rates have been reported with this agent, with a high proportion of treatments completed in a single session.^{41,45,52} In a series of 30 patients with DAVFs with CVR, Cognard et al⁴⁵ achieved a complete cure in 24 patients. Of these 24 patients, 20 cures were achieved after a single procedure.

The use of Onyx is associated with some disadvantages as well. Prolonged fluoroscopic times can occur, and careful attention must be paid to avoid radiation-induced injury.^{41,52} Other reported events including catheter entrapment, angiototoxicity from DMSO, and cranial nerve injury.^{41,46} Many of these complications can be prevented if the operators recognize their potential mechanisms. DMSO-induced angiototoxicity and vasospasm can be prevented by slow Onyx injection.⁴¹ Similarly, catheter retention can be avoided by limiting reflux around the catheter tip and positioning the catheter tip in a relatively straight vessel segment. We avoid Onyx injection into vessels known to supply the lower cranial nerves (petrosal branch of the middle meningeal artery, stylomastoid branch of the posterior auricular and occipital arteries, and jugular branch of the ascending pharyngeal artery). Under these circumstances, alternative suitable vessels for embolization can usually be found. If adequate penetration into the fistula is achieved, the remaining feeders will thrombose spontaneously.

TVE

TVE is performed by retrograde catheterization of the involved dural sinus or cortical vein followed by deposition of coils and/or liquid embolic agents adjacent to the shunt. The aim of this treatment is occlusion of the arteriovenous fistula and/or disconnection of leptomeningeal or cortical reflux with preservation of normal venous drainage. TVE is more safely used when the diseased sinus segment has minimal contributions to normal venous outflow and can be completely occluded. More caution is required when the dural venous sinus maintains drainage of normal veins—in these circumstances,

precise identification of the fistula is essential to avoid potential venous infarction or hemorrhage. Partial embolization of the involved dural sinus should be avoided because the diversion of shunt flow into the normal cerebral venous pathways can lead to worsening CVD.

Benefits of TVE include the relative simplicity of retrograde venous access to the fistulous site and the ability to close the fistula in 1 session. TVE is particularly advantageous for DAVFs with multiple arterial feeders of small size or tortuous course for which complete or practical treatment by TAE is not feasible.^{45,53} Lesions of the cavernous (Fig 4) and transverse/sigmoid sinuses are more optimal for TVE than those involving the superior sagittal sinus.⁵³ The rates of complete angiographic fistula ablation by TVE have been reported at 71%–87.5%.^{53–55}

The risks of TVE include vessel perforation, infarction, intracranial hemorrhage, and transient or permanent neurologic deficits related to changes in venous drainage course.^{55,56} Transient ophthalmoplegia has been reported in 14% of cavernous sinus embolizations,⁵⁵ but patients typically have a full recovery. The risk of cranial nerve damage from coil mass effect or direct coil injury can be avoided through the use of liquid embolic agents. Permanent complications have been reported in 4%–7% of cases.^{53–55} Despite these risks, TVE can be a safe and effective procedure for many DAVFs and can be used as an adjunct to TAE for a complete cure.

Surgery

Due to the efficacy of endovascular treatment, surgery is currently indicated in cases in which endovascular approaches have failed or are not feasible. A variety of options is available, including direct intraoperative embolization of meningeal arteries or veins, resection of abnormal dura, packing of the diseased sinus, disconnection of the retrograde leptomeningeal venous drainage, and skeletonization of the dural sinus with disconnection of the dural arterial supply (Fig 5). Certain anatomic locations of DAVFs are more amenable for surgery. These include the floor of the anterior cranial fossa and the superior sagittal sinus, where arterial access is difficult and/or sacrifice of the sinus is often undesirable.^{57,58} DAVFs that involve eloquent feeders are also better addressed by using a surgical or combined approach to ensure vessel preservation.




Fig 5. A 58-year-old male patient presented with thunder-clap headache and a small subarachnoid hemorrhage centered at the foramen magnum. **A**, Left vertebral angiogram demonstrates a dural fistula at the foramen magnum adjacent to the V4 segment of the left vertebral artery. A dominant feeder is noted arising from the left vertebral artery (arrow), and there is a focal venous varix (arrowhead). The venous drainage was along the perimesencephalic vein into the left superior petrosal sinus (not shown). **B**, Axial DynaCT (Siemens, Erlangen, Germany) reconstruction reveals multiple additional feeders (arrows) that were difficult to appreciate on 2D DSA. The patient underwent an embolization of the larger feeder transarterially, but complete occlusion of the fistula was not accomplished. **C** and **D**, The residual fistula was surgically occluded. A partial C1 laminectomy and suboccipital craniotomy were fashioned. Surgical disconnection of the venous outflow was performed, resulting in complete obliteration of the fistula. The patient made an uncomplicated and complete recovery.

Presurgical arterial embolization can reduce the risk of surgical complications. The efficacy of this combined approach for DAVF ablation has been reported at nearly 100%, but the risk of morbidity and mortality remains considerable at >10%.^{57,59,60}

SRS

Studies of SRS for DAVFs remain preliminary and have primarily involved low-risk lesions or those that are not amenable to endovascular or surgical approaches. Lesions are irradiated with 20–30 Gy, which causes vessel thrombosis and fistula closure during a latency period ranging from several months to a year. Until completion of vessel thrombosis, the hemorrhage risk remains elevated,⁶¹ so SRS is inappropriate as the primary treatment in DAVFs with CVD. Early results have been encouraging, with obliteration rates as high as 93% for combined endovascular embolization and SRS⁶² but have also demonstrated rates as low as 50% when only SRS is used.⁶³ There have also been significant disparities in efficacy depending on the location of the fistula,⁶⁴ reflecting challenges for shunt targeting in complex lesions. Experience with SRS currently remains limited, and this technique should be reserved for carefully selected DAVFs for which endovascular and surgical options have been exhausted.

Conclusions

A number of classification schemes have been devised to aid in the clinical management of DAVFs. The Borden classification stratifies the lesions into 3 types according to the venous drainage pattern (dural venous sinus [types I and II] versus cortical vein [type III] and the presence [types II and III] of cortical venous reflux. These classifications are useful for categorizing lesions as benign or aggressive, but they do not consider the natural history of these lesions. DAVFs are dynamic lesions that may either spontaneously regress or progress, so close attention to any change in symptoms is important because this may signify a change in the type of venous drainage pattern. Additionally, further subdivision of the DAVFs with CVD into

symptomatic and asymptomatic lesions may help stratify high-risk patients and modify treatment planning in the future. Noninvasive imaging evaluation by CTA and MRA can provide useful information for diagnosis, classification, and treatment planning, but the criterion standard for DAVF imaging remains DSA, particularly with the new adjunct of conebeam CT. Treatment should be pursued for all DAVFs with CVD or intolerable symptoms, and management decisions should be approached by a multidisciplinary team that is capable of evaluating all possible therapies.

Acknowledgments

We thank Lydia Gregg, Medical Illustrator and Research Associate, Division of Interventional Neuroradiology, Johns Hopkins School of Medicine, for her contribution with Fig 2.

Disclosures: Dheeraj Gandhi—*UNRELATED:* Consultancy: Covidian, ev3; Grants/Grants Pending: Merlin, aneurysm occlusion device; Other: occasional medicolegal case review with no relevance to this work. James Chen—*UNRELATED:* Other: Doris Duke Charitable Foundation, Comments: Doris Duke Clinical Research Fellowship. Judy Huang—*UNRELATED:* Royalties: Thieme Medical Publishers, Comments: *Fundamentals of Operative Neurosurgery*. 2nd ed. Sudhir Kathurai—*UNRELATED:* Grant/Grants Pending: Siemens.

References

1. Kwon BJ, Han MH, Kang HS, et al. MR imaging findings of intracranial dural arteriovenous fistulas: relations with venous drainage patterns. *AJNR Am J Neuroradiol* 2005;26:2500–07
2. Kirsch M, Liebig T, Kuhne D, et al. Endovascular management of dural arteriovenous fistulas of the transverse and sigmoid sinus in 150 patients. *Neuroradiology* 2009;51:477–83. Epub 2009 Apr 8
3. Morita A, Meyer FB, Nichols DA, et al. Childhood dural arteriovenous fistulae of the posterior dural sinuses: three case reports and literature review. *Neurosurgery* 1995;37:1193–99, discussion 1199–1200
4. Chung SJ, Kim JS, Kim JC, et al. Intracranial dural arteriovenous fistulas: analysis of 60 patients. *Cerebrovasc Dis* 2002;13:79–88
5. Nabors MW, Azzam CJ, Albanna FJ, et al. Delayed postoperative dural arteriovenous malformations: report of two cases. *J Neurosurg* 1987;66:768–72
6. Awad IA, Little JR, Akarawi WP, et al. Intracranial dural arteriovenous malformations: factors predisposing to an aggressive neurological course. *J Neurosurg* 1990;72:839–50
7. Izumi T, Miyachi S, Hattori K, et al. Thrombophilic abnormalities among patients with cranial dural arteriovenous fistulas. *Neurosurgery* 2007;61:262–68, discussion 268–69

8. Kerber CW, Newton TH. The macro and microvasculature of the dura mater. *Neuroradiology* 1973;6:175–79
9. Kojima T, Miyachi S, Sahara Y, et al. The relationship between venous hypertension and expression of vascular endothelial growth factor: hemodynamic and immunohistochemical examinations in a rat venous hypertension model. *Surg Neurol* 2007;68:277–84, discussion 284
10. Fujita A, Kuwamura K, Saitoh M, et al. Cerebral sinus thrombosis in a patient with protein S deficiency: a case report [in Japanese]. *No Shinkei Geka* 1997;25:467–72
11. Gerlach R, Yahya H, Rohde S, et al. Increased incidence of thrombophilic abnormalities in patients with cranial dural arteriovenous fistulae. *Neurol Res* 2003;25:745–48
12. Borden JA, Wu JK, Shucart WA. A proposed classification for spinal and cranial dural arteriovenous fistulous malformations and implications for treatment. *J Neurosurg* 1995;82:166–79
13. Cognard C, Gobin YP, Pierot L, et al. Cerebral dural arteriovenous fistulas: clinical and angiographic correlation with a revised classification of venous drainage. *Radiology* 1995;194:671–80
14. van Dijk JM, terBrugge KG, Willinsky RA, et al. Clinical course of cranial dural arteriovenous fistulas with long-term persistent cortical venous reflux. *Stroke* 2002;33:1233–36
15. Brown RD Jr, Flemming KD, Meyer FB, et al. Natural history, evaluation, and management of intracranial vascular malformations. *Mayo Clin Proc* 2005;80:269–81
16. Davies MA, Ter Brugge K, Willinsky R, et al. The natural history and management of intracranial dural arteriovenous fistulae. Part 2. Aggressive lesions. *Interv Neuroradiol* 1997;3:303–11
17. Davies MA, TerBrugge K, Willinsky R, et al. The validity of classification for the clinical presentation of intracranial dural arteriovenous fistulas. *J Neurosurg* 1996;85:830–37
18. Zipfel GJ, Shah MN, Refai D, et al. Cranial dural arteriovenous fistulas: modification of angiographic classification scales based on new natural history data. *Neurosurg Focus* 2009;26:E14
19. Satomi J, van Dijk JM, Terbrugge KG, et al. Benign cranial dural arteriovenous fistulas: outcome of conservative management based on the natural history of the lesion. *J Neurosurg* 2002;97:767–70
20. Cognard C, Houdart E, Casasco A, et al. Long-term changes in intracranial dural arteriovenous fistulae leading to worsening in the type of venous drainage. *Neuroradiology* 1997;39:59–66
21. Saito A, Furuno Y, Nishimura S, et al. Spontaneous closure of transverse sinus dural arteriovenous fistula: case report. *Neurol Med Chir (Tokyo)* 2008;48:564–68
22. Endo S, Koshu K, Suzuki J. Spontaneous regression of posterior fossa dural arteriovenous malformation. *J Neurosurg* 1979;51:715–17
23. Hansen JH, Sogaard I. Spontaneous regression of an extra- and intracranial arteriovenous malformation: case report. *J Neurosurg* 1976;45:338–41
24. Landman JA, Braun IF. Spontaneous closure of a dural arteriovenous fistula associated with acute hearing loss. *AJNR Am J Neuroradiol* 1985;6:448–49
25. Luciani A, Houdart E, Mounayer C, et al. Spontaneous closure of dural arteriovenous fistulas: report of three cases and review of the literature. *AJNR Am J Neuroradiol* 2001;22:992–96
26. Moriya M, Itokawa H, Fujimoto M, et al. Spontaneous closure of dural arteriovenous fistula after performing diagnostic angiography [in Japanese]. *No Shinkei Geka* 2007;35:65–70
27. Olutola PS, Eliam M, Molot M, et al. Spontaneous regression of a dural arteriovenous malformation. *Neurosurgery* 1983;12:687–90
28. Hurst RW, Bagley LJ, Galetta S, et al. Dementia resulting from dural arteriovenous fistulas: the pathologic findings of venous hypertensive encephalopathy. *AJNR Am J Neuroradiol* 1998;19:1267–73
29. Lucas Cde P, Zabramski JM. Dural arteriovenous fistula of the transverse-sigmoid sinus causing trigeminal neuralgia. *Acta Neurochir (Wien)* 2007;149:1249–53, discussion 1253. Epub 2007 Oct 29
30. Hasumi T, Fukushima T, Haisa T, et al. Focal dural arteriovenous fistula (DAVF) presenting with progressive cognitive impairment including amnesia and alexia. *Intern Med* 2007;46:1317–20
31. Hirano N, Yamadori A, Komiya M. Dural arteriovenous fistula: a cause of hypoperfusion-induced intellectual impairment. *Eur Neurol* 1993;33:5–8
32. Lasjaunias P, Chiu M, ter Brugge K, et al. Neurological manifestations of intracranial dural arteriovenous malformations. *J Neurosurg* 1986;64:724–30
33. Lee PH, Lee JS, Shin DH, et al. Parkinsonism as an initial manifestation of dural arteriovenous fistula. *Eur J Neurol* 2005;12:403–06
34. Zeidman SM, Monsein LH, Arosarena O, et al. Reversibility of white matter changes and dementia after treatment of dural fistulas. *AJNR Am J Neuroradiol* 1995;16:1080–83
35. Brouwer PA, Bosman T, van Walderveen MA, et al. Dynamic 320-section CT angiography in cranial arteriovenous shunting lesions. *AJNR Am J Neuroradiol* 2010;31:767–70
36. Siebert E, Bohner G, Dewey M, et al. 320-slice CT neuroimaging: initial clinical experience and image quality evaluation. *Br J Radiol* 2009;82:561–70
37. Cohen SD, Goins JL, Butler SG, et al. Dural arteriovenous fistula: diagnosis, treatment, and outcomes. *Laryngoscope* 2009;119:293–97
38. Nishimura S, Hirai T, Sasao A, et al. Evaluation of dural arteriovenous fistulas with 4D contrast-enhanced MR angiography at 3T. *AJNR Am J Neuroradiol* 2010;31:80–85
39. Farb RI, Agid R, Willinsky RA, et al. Cranial dural arteriovenous fistula: diagnosis and classification with time-resolved MR angiography at 3T. *AJNR Am J Neuroradiol* 2009;30:1546–51
40. Koenigsberg RA. Spontaneous pulsatile tinnitus secondary to a dural malformation not visualized by magnetic resonance angiography. *Clin Imaging* 1996;20:95–98
41. Nogueira RG, Dabus G, Rabinov JD, et al. Preliminary experience with Onyx embolization for the treatment of intracranial dural arteriovenous fistulas. *AJNR Am J Neuroradiol* 2008;29:91–97
42. Kawaguchi S, Sakaki T, Morimoto T, et al. Surgery for dural arteriovenous fistula in superior sagittal sinus and transverse sigmoid sinus. *J Clin Neurosci* 2000;7(suppl 1):47–49
43. Hoh BL, Choudhri TF, Connolly ES Jr, et al. Surgical management of high-grade intracranial dural arteriovenous fistulas: leptomeningeal venous disruption without nidus excision. *Neurosurgery* 1998;42:796–804, discussion 804–05
44. Mironov A. Selective transvenous embolization of dural fistulas without occlusion of the dural sinus. *AJNR Am J Neuroradiol* 1998;19:389–91
45. Cognard C, Januel AC, Silva NA Jr, et al. Endovascular treatment of intracranial dural arteriovenous fistulas with cortical venous drainage: new management using Onyx. *AJNR Am J Neuroradiol* 2008;29:235–41
46. Toulgoat F, Mounayer C, Tulio Salles Rezende M, et al. Transarterial embolization of intracranial dural arteriovenous malformations with ethylene vinyl alcohol copolymer (Onyx18) [in French]. *J Neuroradiol* 2006;33:105–14
47. Kiyosue H, Hori Y, Okahara M, et al. Treatment of intracranial dural arteriovenous fistulas: current strategies based on location and hemodynamics, and alternative techniques of transcatheter embolization. *Radiographics* 2004;24:1637–53
48. Tomak PR, Cloft HJ, Kaga A, et al. Evolution of the management of tentorial dural arteriovenous malformations. *Neurosurgery* 2003;52:750–60, discussion 760–62
49. Guedin P, Gaillard S, Boulin A, et al. Therapeutic management of intracranial dural arteriovenous shunts with leptomeningeal venous drainage: report of 53 consecutive patients with emphasis on transarterial embolization with acrylic glue. *J Neurosurg* 2010;112:603–10
50. Halbach VP, Higashida RT, Hieshima GB, et al. Treatment of dural fistulas involving the deep cerebral venous system. *AJNR Am J Neuroradiol* 1989;10:393–99
51. Gemmete JJ, Ansari SA, McHugh J, et al. Embolization of vascular tumors of the head and neck. *Neuroimaging Clin N Am* 2009;19:181–98
52. Stiefel MF, Albuquerque FC, Park MS, et al. Endovascular treatment of intracranial dural arteriovenous fistulae using Onyx: a case series. *Neurosurgery* 2009;65:132–39, discussion 139–40
53. Roy D, Raymond J. The role of transvenous embolization in the treatment of intracranial dural arteriovenous fistulas. *Neurosurgery* 1997;40:1133–41, discussion 1141–44
54. Urtasun F, Biondi A, Casaco A, et al. Cerebral dural arteriovenous fistulas: percutaneous transvenous embolization. *Radiology* 1996;199:209–17
55. Yoshida K, Melake M, Oishi H, et al. Transvenous embolization of dural carotid cavernous fistulas: a series of 44 consecutive patients. *AJNR Am J Neuroradiol* 2010;31:651–55
56. Klish J, Huppertz HJ, Spetzger U, et al. Transvenous treatment of carotid cavernous and dural arteriovenous fistulae: results for 31 patients and review of the literature. *Neurosurgery* 2003;53:836–56, discussion 856–57
57. Collice M, D'Aliberti G, Arena O, et al. Surgical treatment of intracranial dural arteriovenous fistulae: role of venous drainage. *Neurosurgery* 2000;47:56–66, discussion 66–67
58. Lucas CP, Zabramski JM, Spetzler RF, et al. Treatment for intracranial dural arteriovenous malformations: a meta-analysis from the English language literature. *Neurosurgery* 1997;40:1119–30, discussion 1130–32
59. Goto K, Sidipratomo P, Ogata N, et al. Combining endovascular and neurosurgical treatments of high-risk dural arteriovenous fistulas in the lateral sinus and the confluence of the sinuses. *J Neurosurg* 1999;90:289–99
60. Kakarla UK, Deshmukh VR, Zabramski JM, et al. Surgical treatment of high-risk intracranial dural arteriovenous fistulae: clinical outcomes and avoidance of complications. *Neurosurgery* 2007;61:447–57, discussion 457–59
61. Guo WY, Pan DH, Wu HM, et al. Radiosurgery as a treatment alternative for dural arteriovenous fistulas of the cavernous sinus. *AJNR Am J Neuroradiol* 1998;19:1081–87
62. Pollock BE, Nichols DA, Garrity JA, et al. Stereotactic radiosurgery and particulate embolization for cavernous sinus dural arteriovenous fistulae. *Neurosurgery* 1999;45:459–66, discussion 466–67
63. Wu HM, Pan DH, Chung WY, et al. Gamma knife surgery for the management of intracranial dural arteriovenous fistulas. *J Neurosurg* 2006;105(suppl):43–51
64. Yang HC, Kano H, Kondziolka D, et al. Stereotactic radiosurgery with or without embolization for intracranial dural arteriovenous fistulas. *Neurosurgery* 2010;67:1276–83, discussion 1284–85